Amanta Healthcare's Strategic Leap: Q3 & 9M FY26 Performance and Future Growth Drivers

Amanta Healthcare Limited, a niche pharmaceutical company with over three decades of legacy in sterile liquids, recently unveiled its Q3 and 9M FY26 financial performance, marking its maiden earnings call as a listed entity. The company reported a robust Q3 FY26 revenue of INR 75 crore, reflecting a 9.8% year-on-year (YoY) growth. For the nine-month period, revenue reached INR 211 crore, a 3.97% YoY increase, underscoring steady demand and volume-led expansion across its diversified portfolio. This performance highlights Amanta Healthcare's disciplined execution and strategic focus on profitability.

The company's operational efficiency was evident in its EBITDA figures. Q3 FY26 EBITDA stood at INR 15 crore, with margins at 20.62%. For the nine-month period, EBITDA increased by 6.06% YoY to INR 45 crore, with margins improving by 42 basis points YoY to 21.31%. This margin expansion is a testament to effective cost control and optimized operational efficiency. Profitability saw a significant boost, with Net Profit for Q3 FY26 rising to INR 5 crore, an 8.1% YoY increase. The nine-month PAT grew by an impressive 51.3% YoY to INR 9 crore, demonstrating a strong turnaround from a loss of INR 2 crore in FY23 to a profit of INR 11 crore in FY25. This trajectory showcases the benefits of operating leverage and continuous improvement in revenue and business sustainability.

Amanta Healthcare's strategic vision is anchored around capacity expansion, operating leverage, and cost efficiency. A key differentiator for the company is its SteriPort platform, a two-port IV fluid container system built on advanced Injection Stretch Blow Moulding (ISBM) technology, offering superior sterilization. SteriPort currently contributes approximately 40% of the company's revenue and operates at a high utilization level of 91%, reflecting strong demand. The company plans to double its SteriPort capacity from 6.6 crore bottles to approximately 12 crore bottles per year with an investment of INR 90 crore. This expansion is expected to generate an incremental revenue of INR 110-120 crore per year and expand EBITDA margins by 3-4%, with commercialization anticipated in Q1 FY27.

In parallel, the Small Volume Parenterals (SVP) segment, a high-margin, export-focused growth engine, is also undergoing expansion. The company is increasing SVP capacity from 21 crore units to 31 crore units per year, targeting an incremental revenue of roughly INR 30 crore. This new SVP line will primarily focus on inhalation solutions (respules), OTC products, and preservative-free unit doses, strengthening the company's position in the high-margin export market. Commercialization for the SVP line is expected by January 2027.

Further demonstrating its commitment to cost efficiency and sustainability, Amanta Healthcare is implementing a 10.8 MW captive solar power plant. This project, with a total cost of INR 34.8 crore (INR 5.8 crore equity, balance debt-funded), is targeted for commissioning in Q1 FY27. It is projected to generate annual power cost savings of INR 9 crore at the EBITDA level, with a simple payback period of 3.6 years. This initiative will not only improve EBITDA margins but also strengthen the company's ESG profile by reducing its carbon footprint.

The company's financial health has also seen significant improvement. The debt-to-equity ratio has reduced by over 40% since FY23, from 3.43x to 2.02x, primarily due to the repayment of Non-Convertible Debentures and a private placement of 2,000,000 shares. This disciplined approach to capital allocation and balance sheet management positions Amanta Healthcare for sustained growth. The company aims for a Revenue CAGR of 20%+ over the next two years and an EBITDA Margin of 25%+, with FY27 revenue projected to be around INR 400 crore.

Amanta Healthcare stands at an important inflection point, transitioning from an investment-led phase to a structurally profitable growth phase. With category leadership, high-margin products, visible capacity-led growth, and improving return metrics, the company is well-positioned to capitalize on rising healthcare demand and tightening quality standards. The management's focus on innovation, operational efficiency, and strategic expansion underscores its commitment to long-term value creation for stakeholders.